pp-265 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Cardiopulmonary bypass surgery
Clinical stage: Phase 3
Modality: Small molecule
Mechanism & Target: Not disclosed
Route & form: Oral
Differentiation:it is a novel cytoprotective preconditioning agent with antioxidant and anti-inflammatory properties being developed for reducing postoperative complications in patients undergoing cardiac surgery.
Manufacturer #39678
A late-stage clinical biopharmaceutical company focused on urology / nephrology. Developing a small molecule therapeutic targeting urology / nephrology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None